Desmoid tumors: old and new drugs for a rare and challenging disease
There has been a paradigm shift in the treatment strategy for patients with desmoid tumor toward less invasive management using systemic therapies. In addition to older drugs, such as conventional chemotherapy and tyrosine kinase inhibitors, the newest class of medical agents—the gamma secretase inh...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
1 January 2025
|
| In: |
Cancer
Year: 2025, Jahrgang: 131, Heft: 1, Pages: 1-2 |
| ISSN: | 1097-0142 |
| DOI: | 10.1002/cncr.35603 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/cncr.35603 Verlag, lizenzpflichtig, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35603 
|
| Verfasserangaben: | Bernd Kasper |
| Zusammenfassung: | There has been a paradigm shift in the treatment strategy for patients with desmoid tumor toward less invasive management using systemic therapies. In addition to older drugs, such as conventional chemotherapy and tyrosine kinase inhibitors, the newest class of medical agents—the gamma secretase inhibitors—have been included in the treatment armamentarium for patients with desmoid tumor, as nicely depicted in the latest consensus guideline from The Desmoid Tumor Working Group. |
|---|---|
| Beschreibung: | Erstmals veröffentlicht: 15. November 2024 Gesehen am 08.05.2025 |
| Beschreibung: | Online Resource |
| ISSN: | 1097-0142 |
| DOI: | 10.1002/cncr.35603 |